Targeted drug delivery

Global Targeted Drug Delivery Partnering Deals and Agreements 2012-2018

Retrieved on: 
Thursday, February 7, 2019
Health sciences, Drug discovery, Pharmacokinetics, Medicinal chemistry, Targeted drug delivery, Drug delivery, Life sciences, Natural sciences

The "Global Targeted Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Targeted Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Targeted Drug Delivery Partnering 2012-2018 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.
  • The report takes the reader through a comprehensive review Targeted Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Targeted Drug Delivery partnering deals.
  • The middle section of the report explores the leading dealmakers in the Targeted Drug Delivery partnering field; both the leading deal values and most active Targeted Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

Genisphere Appoints Biopharmaceutical Veteran, Brian P. McVeigh, to Its Board of Directors

Retrieved on: 
Thursday, December 6, 2018
Drug discovery, Medicinal chemistry, Pharmacokinetics, Targeted drug delivery, McVeigh, Drug delivery, Health

HATFIELD, Pa., Dec. 6, 2018 /PRNewswire/ --Genisphere LLC, provider of the 3DNA nanotechnology drug delivery platform, announced Brian P. McVeigh has joined the company's Board of Directors, bringing expertise to expand activities in business development and investment management.

Key Points: 
  • HATFIELD, Pa., Dec. 6, 2018 /PRNewswire/ --Genisphere LLC, provider of the 3DNA nanotechnology drug delivery platform, announced Brian P. McVeigh has joined the company's Board of Directors, bringing expertise to expand activities in business development and investment management.
  • "Genisphere is delighted to welcome Brian McVeigh to our board of directors," said Tom Bliss, Chief Executive Officer of Genisphere.
  • Mr. McVeigh joins the Genisphere Board as the Company continues to expand its pharmaceutical licensing activities and moves toward commercializing its 3DNA nanocarrier for targeted drug delivery.
  • Genisphere is the provider of the 3DNA platform for targeted drug delivery.

Global Controlled-Release Drug Delivery Market 2018-2025: Drug Clinical Pipeline of 218 Drugs

Retrieved on: 
Friday, November 23, 2018
Pharmacology, Health, Drug delivery, Medical equipment, Pharmaceutical industry, Medicinal chemistry, Drug discovery, Pharmacokinetics, Targeted drug delivery, Camurus

This report on the "Controlled Release Drug Delivery Market" is a result of intensive study of the novel segment and its future market potential.

Key Points: 
  • This report on the "Controlled Release Drug Delivery Market" is a result of intensive study of the novel segment and its future market potential.
  • Global Controlled Release Drug Clinical Pipeline by Phase, Indication, Drug Class
    Global Controlled Release Drug Clinical Pipeline: 218 Drugs
    Majority Drugs In Phase-II & Phase-III Trials: More Than 80
    Controlled drug delivery technology is the one of the most rapidly advancing area in human healthcare management and already had an enormous impact on medical technology with the potential to improve health.
  • Polymeric controlled drug delivery is the most applied strategy towards the controlled drug delivery.
  • The report has been made with key focus on the current market trends, superiority of Controlled Drug Delivery methods to traditional drug delivery methods.